Ikko Tomisaki1, Mirii Harada2, Kei Tokutsu3, Akinori Minato2, Yujiro Nagata2, Rieko Kimuro2, Masahiro Matsumoto2, Naohiro Fujimoto2. 1. Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan; ikko@med.uoeh-u.ac.jp. 2. Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan. 3. Department of Public Health, University of Occupational and Environmental Health, Kitakyushu, Japan.
Abstract
BACKGROUND/AIM: To clarify the clinical significance of the temporary elevated C-reactive protein (CRP) levels followed by a decrease below baseline (CRP flare response) after administration of pembrolizumab to patients with advanced urothelial carcinoma (UC). PATIENTS AND METHODS: We retrospectively reviewed 31 patients with advanced UC who received pembrolizumab. Patients were categorized into 3 groups (flare-responder, responder, non-responder) according to early CRP kinetics. Intergroup tumor response and survivals were compared. RESULTS: Objective response rates of flare-responder, responder, and non-responder groups were 75%, 80%, and 26%, respectively. Median overall survival was not reached in flare-responder and responder groups, and was 10.2 months in the non-responder group (p=0.03). Furthermore, the flare-responder group did not reach median progression-free survival, and for the responder and non-responder groups it was 15.2 and 2.8 months, respectively (p=0.03). CONCLUSION: CRP flare response might be a promising biomarker in patients with advanced UC who received pembrolizumab.
BACKGROUND/AIM: To clarify the clinical significance of the temporary elevated C-reactive protein (CRP) levels followed by a decrease below baseline (CRP flare response) after administration of pembrolizumab to patients with advanced urothelial carcinoma (UC). PATIENTS AND METHODS: We retrospectively reviewed 31 patients with advanced UC who received pembrolizumab. Patients were categorized into 3 groups (flare-responder, responder, non-responder) according to early CRP kinetics. Intergroup tumor response and survivals were compared. RESULTS: Objective response rates of flare-responder, responder, and non-responder groups were 75%, 80%, and 26%, respectively. Median overall survival was not reached in flare-responder and responder groups, and was 10.2 months in the non-responder group (p=0.03). Furthermore, the flare-responder group did not reach median progression-free survival, and for the responder and non-responder groups it was 15.2 and 2.8 months, respectively (p=0.03). CONCLUSION: CRP flare response might be a promising biomarker in patients with advanced UC who received pembrolizumab.
Authors: Daniel T Fisher; Qing Chen; Joseph J Skitzki; Jason B Muhitch; Lei Zhou; Michelle M Appenheimer; Trupti D Vardam; Emily L Weis; Jessica Passanese; Wan-Chao Wang; Sandra O Gollnick; Mark W Dewhirst; Stefan Rose-John; Elizabeth A Repasky; Heinz Baumann; Sharon S Evans Journal: J Clin Invest Date: 2011-09-19 Impact factor: 14.808
Authors: Y Fradet; J Bellmunt; D J Vaughn; J L Lee; L Fong; N J Vogelzang; M A Climent; D P Petrylak; T K Choueiri; A Necchi; W Gerritsen; H Gurney; D I Quinn; S Culine; C N Sternberg; K Nam; T L Frenkl; R F Perini; R de Wit; D F Bajorin Journal: Ann Oncol Date: 2019-06-01 Impact factor: 32.976